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INTRODUCTION
Malaria is a worldwide public health problem because it is a 
medical emergency with a high risk of mortality [1]. Plasmodi-
um falciparum causes the most dangerous form of malaria to 
humans [2]. It also exhibits resistance to antimalarial drugs [3]. 
The resurgence of malaria is partly attributed to wide distribu-
tion of drug-resistant strains [4]. The enzyme protein farnesyl-
transferase is an ideal drug target for P. falciparum [5]. Farnesyl-
transferase is an enzyme that belongs to the prenyltransferase 
group [6]. It catalyzes the posttranslational modification of in-
tracellular signal transduction proteins by transferring the farne-
syl residue of farnesyl pyrophosphate [7]. The cysteine residue, 
which is the transferring farnesyl residue, belongs to the car-
boxy-terminal consensus sequence called the CAAX motif [7]. 
The targets of farnesyltransferase include members of the Ras 
superfamily, which are critical to cell cycle progression [8]. For 
this reason, inhibitors of farnesyltransferase have effects on an-
ti-cancer drugs and anti-parasitic agents [7]. Therefore, FTIs has 
been recommended as a novel antimalarial drug [9]. 
Mitochondria have been shown to play a key role in the 
apoptotic process through several signaling pathways. Mito-
chondria control the apoptosis at several levels such as main-
tenance of ATP production and mitochondrial membrane po-
tential (ΔΨm) and permeability for the release of certain apop-
togenic factors from the intermembrane space into the cytosol 
[10]. Malaria parasites have very small mitochondrial genomes, 
including 3 encoded proteins, and highly fragmented ribo-
somal RNAs [11]. The mitochondria of P. falciparum enable it 
to adapt to the host morphologically and physiologically [12]. 
The energy metabolism of P. falciparum differs from that of the 
other mammalian hosts [12]. P. falciparum has a simplified 
metabolism with biosynthetic pathways [11]. The mitochon-
dria of P. falciparum do not exhibit full oxidation of glucose to 
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Abstract: The parasite Plasmodium falciparum causes severe malaria and is the most dangerous to humans. However, it 
exhibits resistance to their drugs. Farnesyltransferase has been identified in pathogenic protozoa of the genera Plasmodi-
um and the target of farnesyltransferase includes Ras family. Therefore, the inhibition of farnesyltransferase has been sug-
gested as a new strategy for the treatment of malaria. However, the exact functional mechanism of this agent is still un-
known. In addition, the effect of farnesyltransferase inhibitor (FTIs) on mitochondrial level of malaria parasites is not fully 
understood. In this study, therefore, the effect of a FTI R115777 on the function of mitochondria of P. falciparum was in-
vestigated experimentally. As a result, FTI R115777 was found to suppress the infection rate of malaria parasites under in 
vitro condition. It also reduces the copy number of mtDNA-encoded cytochrome c oxidase III. In addition, the mitochon-
drial membrane potential (ΔΨm) and the green fluorescence intensity of MitoTracker were decreased by FTI R115777. 
Chloroquine and atovaquone were measured by the mtDNA copy number as mitochondrial non-specific or specific inhib-
itor, respectively. Chloroquine did not affect the copy number of mtDNA-encoded cytochrome c oxidase III, while atova-
quone induced to change the mtDNA copy number. These results suggest that FTI R115777 has strong influence on the 
mitochondrial function of P. falciparum. It may have therapeutic potential for malaria by targeting the mitochondria of par-
asites.
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fuel mitochondrial ATP synthesis in the malaria parasite [11]. 
The mitochondrial electron transport chain (mETC) is impor-
tant for pyrimidine biosynthesis [11]. The mitochondria of P. 
falciparum are promising targets for antimalarial drugs because 
the energy-transducing pathways are distinct in the malaria 
parasite [12]. Thus, the inhibition of mitochondria has been 
suggested as a novel strategy for malaria extermination. How-
ever, the relationship between FTIs and mitochondria function 
of P. falciparum has not yet been investigated.  
In this study, the effects of FTI (Zarnestra, R115777) on the 
mitochondrial function of P. falciparum were investigated un-
der in vitro condition. In addition, to compare the drug target, 
after treating chloroquine and atovaquone in vitro, the copy 
number of mtDNA-encoded cytochrome c oxidase III was 
measured for each case. The function of mitochondria was ex-
amined by staining with the mitochondrial membrane poten-
tial (ΔΨm)-sensitive dyes and MitoTracker.
MATERIALS AND METHODS
Chemicals 
FTI was purchased from Selleck (Zarnestra, R115777, Hous-
ton, Texas, USA). Chloroquine and atovaquone were purchased 
from Sigma-Aldrich (St. Louis, Missouri, USA).
Parasite culture
P. falciparum (3D7 strain) was maintained in human eryth-
rocytes (blood group O+) in RPMI 1640 (buffered with 25 mM 
HEPES and 25 mM NaHCO3) supplemented with 10 μg/ml 
gentamycin and 370 μM hypoxanthine under a gas mixture 
containing 5% CO2, 5% O2, and 90% N2 at 37˚C in an incuba-
tor. Parasites were diluted with 9.5 ml of culture medium con-
taining 0.5 ml of sufficient non-infected human erythrocytes 
to yield a final hematocrit of 5% and a parasitemia of 0.5% 
[13]. 
Giemsa staining
A thin blood smear was fixed with 99% methanol for 5 min. 
After fixing the slide, it was dried for 1 min to 2 min. A diluted 
Giemsa solution (Merck, Darmstadt, Germany) was prepared 
prior to staining. The slide was immersed in freshly prepared 
Giemsa stain solution for 25 min, rinsed with tap water, and 
dried. The stained malaria parasites were examined using a 
microscope with a 100×  oil immersion objective lens.
Synchronization of P. falciparum
Synchronized ring-form cultures were tested to investigate 
the antimalarial effects. Sorbitol (5%) was dissolved in dis-
tilled water, and passed through a Millipore filter of 0.22 μm 
pores. Sorbitol (9 ml) was added to 1 ml of the culture pellet, 
and incubated for 5 min in room temperature. The superna-
tant was removed by centrifugation, and the pellet was washed 
3 times in complete media. P. falciparum was determined to be 
free of schizonts by microscopic examination of the Giemsa-
stained specimen [14]. After synchronization, ring form of P. 
falciparum were treated with each drugs for 48 hr. The infection 
rate in synchronized P. falciparum was approximately 1.8-2.0%.
MitoTracker labeling
To measure the mitochondria mass, MitoTracker Green was 
treated in malaria-infected RBCs after FTI R115777 treatment 
for 48 hr. The 9 ml of supernatant of malaria-infected RBCs 
was removed by centrifuge and malaria-infected RBCs were in-
cubated with 1 mM MitoTracker stock solution for 30 min at 
37˚C. After staining with a MitoTracker dye, the malaria-infect-
ed RBCs were washed in incomplete media. Fluorescence im-
aging techniques were employed with the excitation and emis-
sion wavelength bands centered at 490 and 516 nm, respec-
tively. Fluorescence was measured by a CytoFluor fluorescence 
multiwell plate reader (Tecan USA, Durham, North Carolina, 
USA). Fluorescence signal intensities were evaluated using Im-
age J software (ImageJ 1.46r software, U.S. National Institutes 
of Health, Bethesda, Maryland, USA).
Determination of mitochondrial membrane potential 
(ΔΨm)
Variations in ΔΨm were analyzed using 5, 5´ , 6 ,6´ -tetrachlo-
ro-l, l´ , 3, 3´ -tetraethylbenzimidazolcarbocyanine iodide (JC-1) 
(Molecular Probes, Invitrogen, Eugene, Oregon, USA), which 
was stained as previously described [15]. Malaria parasite in-
fected RBCs treated with FTI R115777 for 48 hr were incubated 
with JC-1 reagent for 20 min at 37˚C. The supernatant was re-
moved by centrifugation, and the pellet was washed 3 times in 
Cell-Based Assay buffer (Molecular Probes, Invitrogen). Malar-
ia-infected RBCs were analyzed using a CytoFluor fluorescence 
multiwell plate reader. For healthy conditions, JC-1 forms J-ag-
gregates in excitation and emission wavelengths of 560 and 
595 nm, respectively. For apoptotic or unhealthy conditions, 
JC-1 exists as a monomer at 485 and 535 nm. Fluorescence 
signal intensities were measured using Image J software.
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Determination of oxygen gradients 
P. falciparum was treated with FTI R115777 for 48 hr after 
sorbitol synchronization. The sensor foil (SF-RPSU4, PreSens 
Precision Sensing GmbH, Regensburg, Germany) was calibrat-
ed by placing a drop of sodium dithionate (Na2S4O4), and re-
cording the image [16]. The oxygen concentration was evalu-
ated using VisiSens Analytical 1 software. After recording the 
calibration value, the sensor foil was sterilized by 70% ethanol, 
and washed with autoclaved distilled water several times. Ma-
laria-infected RBCs were placed on the oxygen-sensitive sensor 
foil, and data were read using a detector unit.
Detection of reactive oxygen species (ROS) content by 
dichlorofluorescein (DCF)
To measure ROS activity, an OxiSelect ROS assay kit (Cell 
Biolabs, San Diego, California, USA) was used as previously 
described [17]. The assay uses the diffusion of 2´ ,7´ -dichlorodi-
hydrofluorescin diacetate (DCFH-DA) into cells. DCFH-DA is 
deacetylated by cellular esterases to non-DCFH and rapidly 
oxidized to DCF by ROS. In brief, malaria-infected RBCs were 
pre-incubated with DCFH-DA (100 μM) for 20 min before 
adding FTI R115777. A CytoFluor Fluorescence Multiwell Plate 
Reader (Tecan USA) was used to determine ROS production 
by comparing the results with a predetermined DCF standard 
curve (excitation=480 nm, emission=520 nm). Fluorescence 
signal intensities were measured using Image J software.
Isolation of mitochondrial DNA
P. falciparum was maintained for 48 hr in drugs for treatment 
after sorbitol synchronization. The mtDNA was isolated using 
mtDNA Extractor CT kits (Wako pure Chemical Industries, Ltd., 
Osaka, Japan) following the manufacturer’s instructions [18]. 
Malaria parasites were homogenized in ice-cold homogeniza-
tion buffer provided in the kit. The homogenate was centri-
fuged at 1,000 g and 4˚C for 1 min. The supernatant was col-
lected and centrifuged at 10,000 g and 4˚C for 10 min. The 
mtDNA extraction solutions in the kit were added to the pel-
let. mtDNA was precipitated by the addition of 300 μl of sodi-
um iodide solution and 500 μl of isopropanol. The mtDNA 
concentrations were measured using Nano-Drop (Thermo Sci-
entific, Wilmington, Delaware, USA). 
mtDNA amplification
All oligonucleotide primers were used as described in Cunha 
et al. [19]. The sequences of cytochrome c oxidase III (GenBank 
accession nos. GI8346992 and M76611) expressed from P. fal-
ciparum used in this study were Pf1 (5´ -CCTGCATTAACATCAT-
TATATGGTACATCT-3´ ) and Pf2 (5´ -GATTAACATTCTTGATGAA-
GTAATGATAATACCTT-3´ ) [19]. PCR was conducted using Ac-
cupower PCR premix (Bioneer, Daejeon, Korea). The equiva-
lent amount of the mtDNA were used. All procedures were 
performed according to the manufacturer’s instructions. The 
amplification conditions were as follows: 1 denaturation cycle 
at 96˚C for 10 min; 30 cycles at 95˚C for 1 min and 60˚C for 5 
min; and a final extension at 60˚C for 1 hr. All amplifications 
were performed in a MyGenie 96 Gradient Thermal Block (Bi-
oneer). The PCR products were resolved with standard agarose 
gel electrophoresis, and visualized using ethidium bromide 
staining under UV light. 
Statistical analysis
All statistical data were analyzed using SPSS t-test (IBM, Chi-
cago, Illinois, USA) at 95% coverage. 
RESULTS
Growth inhibitory activity of FTI R115777
To elucidate the antimalarial effects of FTI R115777, P. falci-
parum was treated with the drug for 48 hr. Before treating drugs, 
parasitemia in synchronized P. falciparum was approximately 
1.8-2.0%. Parasitemia after drug treatment was 13.4±0.3% in 
the control group. FTI R115777 inhibited the proliferation of 
malaria parasites in a dose-dependent manner. The IC50 for FTI 
R115777 for P. falciparum 3D7 was 11.48 nM in vitro. FTI 
R115777 (100 nM) inhibited the growth of parasites by 65.2±  
1.8% (Fig. 1A). Malaria parasitemias became 5.8%, 5,6%, and 
3.0% after addition of 0.05, 0.1, and 0.5 μM of FTI R115777, 
respectively. The high-dose FTI R115777-treated P. falciparum 
group exhibited distinctive morphological features, such as 
pyknosis form, compared with the control group (Fig. 1A). In 
addition, we treated atovaquone, known to target the mito-
chondria, and chloroquine that does not have a specific mito-
chondrial effect [20,21]. Chloroquine and atovaquone were 
observed to inhibit P. falciparum infection as coincided with 
Fig. 1B and 1C. Malaria parasitemias became 6.8%, 5.7%, and 
1.7% after addition of 10, 100, and 100 nM of chloroquine, re-
spectively (Fig. 1B). When 0.1, 1, and 10 nM of atovaquone 
was treated, parasitemia was 7.7%, 5.9%, and 1.2%, respec-
tively (Fig. 1C). These results showed the antimalarial effect of 
FTI R115777, cloroquine, and atovaquone. 
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Maintenance of mitochondrial membrane potential ΔΨm
Given that FTI R115777 suppresses the proliferation of P. 
falciparum, we investigated whether this action works specifi-
cally through the mitochondria. As shown in Fig. 2A and B, 
the low-dose FTI R115777-treated group exhibited strong red 
fluorescence, which indicated a healthy condition. By contrast, 
the high-dose R115777-treated group exhibited green fluores-
cence because of low ΔΨm compared with that of the control 
group. These results showed that mitochondrial depolariza-
tion was induced by FTI R115777.
Intensity of MitoTracker green fluorescence in FTI 
R115777-treated malaria parasites
To investigate the effect of FTI R115777 on the mitochondrial 
function of P. falciparum, MitoTracker green fluorescence was 
stained in vitro. MitoTracker labels the mitochondria in live 
cells using ΔΨm, and can be used for multiple labeling and 
measuring of the depolarized mitochondrial mass [22,23]. The 
cells stained by MitoTracker were observed under fluorescence 
microscopy, and the fluorescence signal intensities were mea-
sured using Image J software. Fig. 2C and D clearly show that 
the MitoTracker green fluorescence signal decreased as the dose 
of FTI R115777 increased. This result indicated that FTI R115777 
can be used as an effective target to mitochondria.
Oxygen concentration of FTI R115777-treated malaria 
parasites 
To examine the mitochondrial activity, extracellular oxygen 
concentrations were measured via the ratiometric read-out of 
the sensor foil by VisiSens devise. The oxygen gradient of FTI 
R115777-treated P. falciparum were shown on the sensor foil 
(Fig. 3A). As shown in Fig. 3B, the oxygen concentration of 
malaria-infected RBCs was higher than that of the non-infect-
ed RBCs (P<0.05). However, the average oxygen concentra-
tion started to decrease slightly from the dose of 0.1 μM to 1 
μM FTI R115777. This result implied that depolarization was 
mainly mediated by other contributors rather than oxygen 
consumption. 
Effect of FTI on the intracellular ROS level
We investigated whether FTI R115777-treated P. falciparum 
was linked to mitochondrial ROS generation. The DCFH-DA-
measurable ROS induced by FTI R115777 in the malaria para-
sites was measured. ROS levels notably increased in malaria-
infected RBCs than those in non-infected RBCs. The intracel-
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Fig. 1. Effect of 3 antimalarial drugs on the proliferation of P. falci-
parum. (A) Proliferation assay of FTI R155777-treated P. falciparum 
for 48 hr and corresponding Giemsa staining. (B) Proliferation as-
say of chloroquine-treated P. falciparum and Giemsa staining. (C) 
Proliferation assay of atovaquone-treated P. falciparum and Giem-
sa staining. 
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lular ROS levels increased as the dose of FTI R115777 increas-
ed (Fig. 3C). This result indicated that the FTI R115777-induc-
ed intracellular ROS could sufficiently disrupt the mitochon-
drial functions. The specificity of FTI R115777 could be attrib-
uted to the selective interaction with malarial mitochondria. 
This interaction may specifically generate ROS in malarial mi-
tochondria, which are key factors that enable the manifesta-
tion of the antimalarial drug effect of FTI R115777. 
Copy number of cytochrome c oxidase III in FTI 
R115777-treated P. falciparum
In this study, we measured the copy number of mtDNA-en-
coded cytochrome c oxidase III in FTI R115777-treated P. falci-
parum. FTI R115777 was observed to reduce the copy number 
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Fig. 2. Analysis of mitochondrial membrane potential (ΔΨm) after 48 hr of FTI R115777 treatment using the potential-dependent aggre-
gate-forming lipophilic cation JC-1 (5, 5´, 6, 6´-tetrachloro-1, 1´, 3, 3´-tetraethylbenzimidazole carbocyanide iodide). (A) JC-1 staining. 
Red fluorescence represents mitochondria with intact membrane potential, whereas green fluorescence indicates de-energized mito-
chondria. (B) JC-1 red/green fluorescence intensity. (C) Immunofluorescence analysis of FTI R115777-treated P. falciparum cells for 48 
hr stained with MitoTracker green. (D) Fluorescence intensity of MitoTracker green in FTI R115777-treated P. falciparum. Bars denote 
SD. *P<0.05.
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of mtDNA-encoded cytochrome c oxidase III. The contents 
were dependent on the dose of FTI R115777, as shown in Fig. 
4A and B. Atovaquone and chloroquine have been used as mi-
tochondrial specific inhibitor and general parasite inhibitor, 
respectively. The copy number of mitochondrial DNA-encod-
ed cytochrome c oxidase III was compared for chloroquine 
and atovaquone-treated P. falciparum. Chloroquine did not af-
fect the copy number of mtDNA-encoded cytochrome c oxi-
dase III, while atovaquone increased the corresponding copy 
number (Fig. 4C-F). These results suggested that mtDNA-en-
coded cytochrome c oxidase III of P. falciparum can be a poten-
tial target of FTI R115777. 
DISCUSSION
FTIs are selective inhibitors of intracellular farnesyltransfer-
ase (FTase). FTIs are substrates for prenylation via FTase, in-
cluding Ras, Pho-B, Rac, Pheb, nuclear lamins, and centromer-
ic proteins, which interact with microtubules to promote the 
completion of mitosis [24]. FTase inhibition prevents the post-
translational processing of Ras proteins, which exert effects on 
multiple mechanisms of cellular survival, including angiogen-
esis, cellular adhesion, and mitosis [24]. FTI R115777 (Zarnes-
tra, Tipifarnib) is a nonpeptidomimetic FTI with clinical ability 
in some cancers, such as metastatic breast cancer, leukemia, 
and metastatic glioma [25]. A previous study demonstrated 
the cytotoxicity of FTIs to P. falciparum. The IC50 of FTIs ranges 
from 0.7 nM to 1,000 nM in vitro [5]. Thus, FTI is a promising 
antimalarial agent. However, the target of FTIs in organelles 
such as mitochondria has not yet been investigated. 
The mitochondrion in malaria parasites has a unique bran-
ched tricarboxylic acid metabolism without any activation of a 
pyruvate dehydrogenase. It does not show ATP production in 
blood stages of the parasite. A previous study has shown that 
mitochondrial electron transport chain of P. falciparum is in-
volved in pyrimidine biosynthesis enzyme dihidroorotate de-
hydrogenase in blood stages [26]. In addition, it generates an 
electrochemical proton gradient across the inner membrane of 
mitochondrion that is utilized by the ATP synthase to drive the 
synthesis of ATP. The functional consequence of ATP synthase 
is interesting, because oxidative phosphorylation is not a ma-
jor source of ATP in P. falciparum blood stages. Therefore, mito-
chondria of Plasmodium could be a target for antimalarial 
drugs [11]. Mitochondrial dysfunction can induce apoptotic 
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Fig. 3. Variations in oxygen concentration and ROS production in FTI R115777-treated P. falciparum. (A) Oxygen gradient of FTI R115777-
treated P. falciparum on the sensor foil. (B) Variation in oxygen level of FTI R115777-treated P. falciparum. (C) Variation in intercellular ROS 
level in FTI R115777-treated P. falciparum. Bars denote SD. *P<0.05.
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pathways [27]. The mitochondria control apoptosis at several 
levels, such as maintenance of ATP production and ΔΨm and 
mitochondrial membrane permeability, to release certain apop-
togenic factors from the intermembrane spaces into the cyto-
sol [10]. Thus, ΔΨm is a governing parameter of mitochondri-
al functions and cell health [27]. Changes in ΔΨm are observ-
ed by staining with JC-1, a lipophilic cationic dye that selec-
tively penetrates the mitochondria. This study shows that mi-
tochondrial depolarization were induced by FTI R115777 dose 
dependently (Fig. 2).
The membrane potential generated by ATPase and mitochon-
drial electron transport chain (mETC) may be necessary because 
of the low oxygen consumption rate of P. falciparum. The de-
crease in ATP utilization inhibits oxygen consumption. More-
over, the respiration rate increases when ATP synthesis increases, 
thereby leading to the concept of respiratory control by ADP 
phosphorylation [28]. Oxygen is a terminal acceptor in the mi-
tochondrial electron transport chain (mETC). Thus, the intra-
Fig. 4. Variation in copy number determined by PCR for mito-
chondrial cytochrome c oxidase III. (A, B) Copy number of mtDNA 
cytochrome c oxidase III in FTI R115777-treated P. falciparum. (C, 
D) Copy number of mtDNA cytochrome c oxidase III in chloroquine-
treat ed P. falciparum. (E, F) Copy number of mtDNA cytochrome 
c oxidase III in atovaquone-treated P. falciparum.  
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cellular oxygen concentration has critical functions in physio-
logical and pathological processes [29]. In a previous study, the 
extracellular and intracellular oxygen concentrations were as-
sumed to be similar [29]. In the present study, we observed that 
the oxygen concentration of malaria-infected RBCs was higher 
than that of the non-infected RBCs. However, FTI R115777 did 
not affect the oxygen level in malaria-infected RBCs (Fig. 3A, B). 
The mitochondria depolarization by FTI R115777 could be af-
fected by other factors than oxygen consumption. 
Mitochondria are crucial cellular energy-transducing organ-
elles that function as a large source of ROS. ROS production can 
be controlled by ΔΨm. Dissipation of ΔΨm leads to uncoupling 
of the electron transport chain [30]. ROS are required for mos-
quitoes to induce effective immune responses against Plasmodi-
um [31]. Therefore, mitochondrial ROS are important activators 
in the immune response of the host to malaria infection [32]. 
The generation of ROS has been known to have a crucial func-
tion in the development of systemic complications in malaria 
[33]. In this study, ROS levels significantly increased in malaria-
infected RBCs than in non-infected RBCs. In addition, FTI 
R115777 induced the level of the intracellular ROS. This is true 
that FTI R115777-induced intracellular ROS could sufficiently 
disrupt the mitochondrial functions. The specificity of FTI 
R115777 could be attributed to the selective interaction with ma-
larial mitochondria. This interaction may specifically generate 
ROS in malarial mitochondria, which are key factors that enable 
the manifestation of the antimalarial drug effect of FTI R115777. 
The mitochondrial electron transport system can be used as 
a target for antimalarial drugs of P. falciparum [34]. In intra-ery-
throcytic malaria parasites, the mitochondrial electron trans-
port system transfers the reducing equivalents generated by di-
hydroorotate dehydrogenase of the de novo pyrimidine bio-
synthetic pathway to ubiquinol-cytochrome c reductase [34]. 
The cytochrome c oxidase complex conducts the final step of 
electron transport in malaria parasites [35]. Plasmodium cyto-
chrome c oxidase has the most streamlined subunit composi-
tion among eukaryotes [36]. Thus, the expression of cytochrome 
c oxidase represents the functions of Plasmodium. Cytochrome 
c is released from mitochondria early in apoptosis before mi-
tochondrial depolarization, activation of caspases, and DNA 
fragmentation [37]. 
Atovaquone which was introduced in the early stage of anti-
malarial drug development, has been known to inhibit the ac-
tivity of cytochrome c reductase in cholate-lysed mitochondria 
from P. falciparum and P. yoelii. It works on the cytochrome bc1 
complex in the malarial respiratory chain [38]. The role of mi-
tochondria of malaria parasites is to dispose electrons generat-
ed by dihydroorotate dehydrogenase which is an essential en-
zyme in pyrimidine biosynthesis [38]. Therefore, the inhibi-
tion of dihydroorotate dehydrogenase has been suggested as 
antimalarial compounds, such as atovaquone [38]. 
In this study, we isolated the mitochondrial DNA and mea-
sured the copy number of mitochondrial DNA-encoded cyto-
chrome c oxidase from FTI R115777-treated P. falciparum. FTI 
R115777 inhibits the copy number of mitochondrial cytoch-
rome c oxidase dose dependently. mtDNA copy number were 
measured after treatment of chloroqunine and atovaquone as 
mitochondrial non-specific or specific inhibitor, respectively. 
FTI R115777 and atovaquone shows differences in the copy 
number of mtDNA-encoded cytochrome c oxidase III. These 
drugs may act as a target of mitochondria through the distin-
guished mechanisms. To explain this different response of the 
copy number of mtDNA-encoded cytochrome c oxidase III by 
FTI R115777 and atovaquone needs to be verified through a 
further study in the future.  
The effect of FTI R115777 on mitochondria of P. falciparum 
was in vitro analyzed in this study. The FTI R115777 was ob-
served to inhibit the growth of malaria parasites effectively. It 
also affected the mitochondrial depolarization and ROS levels. 
The copy number of mtDNA-encoded cytochrome c oxidase 
III was significantly reduced by FTI R115777. The experimental 
data obtained in this study supported that FTI R115777 has 
strong influence on the mitochondria of P. falciparum by dete-
riorating the function of malarial mitochondria. 
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